• CIPPS-UNAM
• 9 abril, 2019
• Conferencias, Simposio

4 DE MARZO DÍA INTERNACIONAL DEL VPH

Introducción

El 4 de marzo ha sido declarado como el día internacional del virus de papiloma humano, VPH, para promover la concientización sobre la importancia de este virus.

¿Qué es?

El  VPH es la infección de transmisión sexual más común tanto en mujeres como en hombres.

¿Por qué es importante?

Hay más de 100 tipos de este virus, los cuales son clasificados en virus de alto y bajo riesgo. La infección persistente por virus de alto riesgo se encuentra asociada a todos los casos de cáncer cervical.

El cáncer cervical es, en nuestros días,  el segundo cáncer más común en las mujeres de todo el mundo. En países en desarrollo, como el nuestro, el cáncer cervical causa la muerte de alrededor de 200 mil mujeres por año.

Además los virus de alto riesgo también se encuentran asociados a cáncer de vagina, vulva, ano, pene y algunos tipos de cáncer oral y faríngeo.

¿Cómo se previene la infección persistente por este virus?

La infección presistente por VPH puede ser prevenida mediante el uso de condón y, sobre todo, mediante la vacunación cuadrivalente (que protege contra 4 tipos) y nanovalente (que protege contra 9 tipos).

Las vacunas protegen contra los virus que causan cáncer y verrugas con mayor frecuencia y pueden ser usadas tanto en mujeres como en hombres.

Si eres mujer y haz comenzado tu vida sexual activa, tienes que realizarte el estudio de Papanicolau  periódicamente para prevenir el desarrollo de cáncer cervical.

 

 

¿Quieres saber más?

ARTÍCULOS Y LIBROS SOBRE VPH

Dr. Jorge Salmerón Castro

1. Torres G, Salmerón J, Tellez M, Lazcano E, Juárez S, Torres I, Gil L, Buiatti E. Call and recall for cervical cancer screening in a developing country: a randomised field trial. International Journal of Cancer. 87 (6):869-873, 2000. ISSN: 0020-7136
2. Lazcano E, Herrero R, Muñoz N, Cruz A, Shah KV, Alonso P, Hernández P, Salmerón J, Hernández M. Epidemiology of HPV infection among Mexican women with normal cervical cytology. International Journal of Cancer. 91(3):412-20, 2001. ISSN: 0020-7136
3. Lazcano E, Rivera L, Arillo E, Salmerón J, Hernández M, Muñoz N. Acceptability of a Human Papillomavirus (HPV) Trial vaccine among mothers of adolescents in Cuernavaca, Mexico. Arch Med Res. 32(3):243-7, 2001. ISSN: 0188-4409
4. Lazcano E, Herrero R, Muñoz N, Hernández M, Salmerón J, Leyva A, Meijer CJ, Walboomers JM. High prevalence of human papillomairus infection in Mexican Males. Comparative study of penil-urethral swabs and urine samples. J Sex Trans Dis. 28(5):277-80, 2001. ISSN: 0148-5717
5. Berumen J, Ordoñez RM, Lazcano E, Salmerón J, Galván SC, Estrada RA, Yunes E, García A, González G, Madrigal A. Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. Journal of the National Cancer Institute. 93(17):1325-1330, 2001. ISSN: 0027-8874
6. Dzuba IG, Yunes E, Allen B, Flores Y, Lazcano E, Shah KV, Bishai D, Lorincz A, Ferris D, Turnbull B, Hernández M, Salmerón J. The acceptability of self-collected samples for HPV testing vs. the Pap test as alternatives in cervical cancer screening. Journal of Women´s Health & Gender-Based Medicine. 11(3):265-275, 2002. ISSN: 1524-6094
7. Flores Y, Shah KV, Lazcano E, Hernández M, Bishai D, Ferris D, Lorincz A, Hernández P, Salmerón J. The Morelos HPV Study Collaborators. Design and methods of the evaluation of an HPV-based cervical cancer screening strategy in Mexico: The Morelos HPV Study. Salud Pública de México. 44(4):335-44, 2002. ISSN: 0036-3634
8. Torres G, Salmerón J, Téllez M, Lazcano E, Juárez S, Torres I, Gil L. Characteristics of respondents to a cervical cancer screening program in a developing country. Arch Med Res. 33:295-300, 2002. ISSN: 0188-4409
9. Salmerón J, Lazcano E, Lorincz A, Hernández M, Hernández P, Leyva A, Uribe M, Manzanares H, Antunez A, Carmona E, Ronnett BM, Sherman ME, Bishai D, Ferris F, Flores Y, Yunes E, Shah KV. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Cancer Causes and Control. 14:505-512, 2003. ISSN: 0957-5243
10. Flores Y, Bishai D, Lazcano E, Shah K, Lorincz A, Hernández M, Salmerón J, The Morelos HPV Study Collaborators. Improving cervical cancer screening in Mexico: Results from the Morelos HPV Study. Salud Pública de México. 45(Supl 3):S388-S398, 2003. ISSN: 0036-3634
11. -Reimpresión (versión en español), con la autorización de Salud Pública de México, En Alonso P, Lazcano EC, Hernández M (Eds). Cáncer Cervicouterino, Diagnóstico, Prevención y Control. (2a edición). Editorial Médica Panamericana, México DF, 2005. 277-289.
12. Pérez-Cruz E, Winkler JL, Velasco-Mondragón E, Salmerón-castro J, García F, Tsu VD, Escandón C, Hernández M. Detección y seguimiento con inspección visual del cérvix para la prevención del cáncer cervicouterino en las zonas rurales de México. Salud Pública de México. 47(1):39-48, 2005. ISSN: 0036-3634
13. Hernández C, Smith J, Lorincz A, Lazcano E, Hernández M, Salmerón J. High-risk human papillomavirus detection and related risk factors among pregnant and non-pregnant women in Mexico. Sexually Transmitted Diseases. 32(10):613-618, 2005. ISSN: 0148-5717
14. Hernández C, Smith J, Lorincz A, Arreola E, Lazcano E, Hernández M, Salmerón J. Prevalencia de infección por virus de papiloma humano (VPH) de alto riesgo y factores asociados en embarazadas derechohabientes del IMSS en Morelos. Salud Pública de México. 47:423-429, 2005. ISSN: 0036-3634
15. Paavonen J, Jenkins D, Bosch F, Naud P, Salmerón J, Wheeler C, Chow S, Alter D, Kitchener H, Castellsague X, de Carvalho N, Skinner S, Harper D, Hedrick J, Jaisamrarn U, Limson G, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G, for the HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. The Lancet. 369: 2161–70, 2007. ISSN: 0140-6736
16. Flores Y, Bishai D, Shah K, Lazcano E, Lorincz A, Hernández M, Ferris D, Salmerón J. Risk factors for cervical cancer among HPV positive women in Mexico. Salud Pública de México. 50(1); 49-58, 2008. ISSN: 0036-3634
17. HPV Study group in men from Brazil, USA and Mexico. Human papillomavirus infection in men residing in Brazil, Mexico, and the USA. Salud Pública de México. 50(5): 408-418, 2008. ISSN: 0036-3634
18. Giuliano A, Lazcano E, Villa L, Flores R, Salmerón J, Lee J, Papenfuss M, Abrahamsen M, Jolles E, Nielson C, Baggio M, Silva R, Quiterio M. The human papillomavirus infection in men study: Human papillomavirus prevalences and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev. 17(8): 2036-43, 2008. ISSN: 1055-9965
19. Herrero R, Ferreccio C, Salmerón J, Almonte M, Sánchez G, Lazcano E, Jerónimo J. New approches to cervical cancer screening in Latin America and the Caribbean. Vaccine. 265:L49-L58, 2008. ISSN: 0264-410X
20. Giuliano A, Lazcano E, Villa L, Flores R, Salmerón J, Lee J, Papenfuss M, Abrahamsen M, Baggio M, Silva R, Quiterio M. Circumcision and sexual behavior: Factors independently associated with human papillomavirus detection among men in the HIM Study. International Journal of Cancer. 124(6):1251-7, 2009. ISSN: 0020-7136
21. Lazcano E, Salmerón J, García A, Aranda C, Madrid V, Gómez C, Martínez O. Recomendaciones para la definición de la política de vacunación contra el virus del papiloma en México. Salud Pública de México. 51(4):336-41, 2009. ISSN: 0036-3634
22. Paavonen J, Naud P, Salmerón J, et al, for the PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomized study in young women. Lancet. 374(9686):301-14, 2009. ISSN: 0140-6736
23. Lazcano E, Lorincz A, Salmerón J, Fernández I, Cruz A, Hernández P, Mejía I, Hernández M. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program. Cancer Causes and Control 10:1693-700, 2010. ISSN: 0957-5243
24. Almonte M, Murillo R, Sanchez G, Jerónimo J, Salmerón J, Ferreccio C, Lazcano E, Herrero R. Nuevos paradigmas y desafíos en la prevención y control del cáncer de cuello uterino en América Latina. Salud Pública de México. 52(6): 544-559, 2010. ISSN: 0036-3634
25. Flores Y, Bishai D, Lörincz A, Shah K, Lazcano E, Hernández M, Granados V, Pérez R, Salmerón J. HPV testing for cervical cancer screening appears more cost-effective than Papanicolaou cytology in Mexico. Cancer Causes Control 22:261–272, 2011. ISSN: 0957-5243
26. Giuliano A, Lee J, Fulp W, Villa L, Lazcano E, Papenfuss M, Abrahamsen M, Salmeron J, Anic G, Rollison D, Smith D. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. The Lancet (377)9769:932-940, 2011. ISSN: 0140-6736
27. Lu B, Viscidi R, Lee J, Wu Y, Villa L, Lazcano E, Carvalho da Silva R, Baggio M, Quiterio M, Salmerón J, Smith D, Abrahamsen M, Papenfuss M, Stockwell H, Giuliano A. Human papillomavirus (HPV) 6, 11, 16, and 18 seroprevalence is associated with sexual practice and age: results from the multinational HPV infection in men study (HIM study). Cancer Epidemiology Biomarkers & Prevention. 20(5):990-1002, 2011. ISSN: 1055-9965
28. Gravitt P, Belinson J, Salmerón J, Shah K. Looking ahead: a case for HPV testing of self-sampled vaginal specimens as a cervical cancer screening strategy. Int J Cancer. 129(3):517-27, 2011. ISSN: 0020-7136
29. Schabath MB, Villa LL, Lazcano-Ponce E, Salmerón J, Quiterio M, Giuliano AR; for the HIM Study. Smoking and Human Papillomavirus (HPV) Infection in the HPV in Men (HIM) Study.Cancer Epidemiol Biomarkers Prev. 21(1):102-110, 2011. ISSN: 1055-9965
30. Nyitray AG, Carvalho da Silva RJ, Baggio ML, Smith D, Abrahamsen M, Papenfuss M, Lin HY, Quiterio M, Salmerón J, Lazcano-Ponce E, Villa LL, Giuliano AR. Six-month incidence, persistence, and factors associated with persistence of anal human papillomavirus in men: the HPV in men study. J Infect Dis. 204(11):1711-22, 2011. ISSN: 0022-1899.
31. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, Salmerón J, Uribe P, Velasco-Mondragón E, Nevarez PH, Acosta RD, Hernández-Avila M. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet. 378(9806):1868-73, 2011. ISSN: 0140-6736
32. Lu B, Viscidi RP, Wu Y, Lee JH, Nyitray AG, Villa LL, Lazcano-Ponce E, Carvalho da Silva RJ, Baggio ML, Quiterio M, Salmeron J, Smith DC, Abrahamsen ME, Papenfuss MR, Stockwell HG, Giuliano AR. Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men. Cancer Res. 72(3):676-85, 2011. ISSN: 0008-5472.
33. Anic GM, Lee JH, Stockwell H, Rollison DE, Wu Y, Papenfuss MR, Villa LL, Lazcano-Ponce E, Gage C, Silva RJ, Baggio ML, Quiterio M, Salmerón J, Abrahamsen M, Giuliano AR. Incidence and Human Papillomavirus (HPV) Type Distribution of Genital Warts in a Multinational Cohort of Men: The HPV in Men Study. J Infect Dis. 204(12):1886-92, 2011. ISSN: 0022-1899.
34. Szarewski A, Poppe W, Skinner R; Wheeler C, Paavonen J, Naud P, Salmeron J, Chow S, Apter D, Kitchener H, Castellsague X, Teixeira J, Hedrick J, Jaisamrarn U, Limson G, Garland S, Romanowski B, Aoki F, Schwarz T, Bosch X, Harper D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV-16/18. International Journal of Cancer. 131(1):106-116, 2012. ISSN: 0020-7136
35. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, De Carvalho NS, Germar MJ, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G; for the HPV PATRICIA Study Group. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13(1):89-99, 2012. ISSN: 1470-2045
36. Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmerón J, Chow SN, Apter D, Kitchener H, Teixeira JC, Skinner SR, Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Harper DM, Huh W, Hardt K, Zahaf T, Descamps D, Struyf F, Dubin G, Lehtinen M; for the HPV PATRICIA Study Group. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13(1):100-10, 2012. ISSN: 1470-2045
37. Repp KK, Nielson CM, Fu R, Schafer S, Lazcano-Ponce E, Salmerón J, Quiterio M, Villa LL, Giuliano AR; for the HIM study. Male Human papillomavirus prevalence and Association with condom use in Brazil, Mexico, and the United States. J Infect Dis. 205(8):1287-93, 2012. ISSN: 0022-1899.
38. Lu B, Viscidi RP, Wu Y, Nyitray AG, Villa LL, Lazcano-Ponce E, Carvalho da Silva RJ, Baggio ML, Quiterio M, Salmeron J, Smith DC, Abrahamsen ME, Papenfuss MR, Giuliano AR. 1. Seroprevalence of Human Papillomavirus (HPV) Type 6 and 16 Vary by Anatomic Site of HPV Infection in Men. Cancer Epidemiol Biomarkers Prev. 21(9):1542-6, 2012. ISSN: 1055-9965
39. Morales R, Parada R, Giuliano AR, Cruz A, Castellsague X, Salmeron J, Lazcano Ponce E. HPV in Female Partners Increases Risk of Incident HPV Infection Acquisition in Heterosexual Men in Rural Central Mexico. Cancer Epidemiol Biomarkers Prev. 21(11):1956-65, 2012. ISSN: 1055-9965
40. Roset Bahmanyar E, Paavonen J, Naud P, Salmerón J, Chow SN, Apter D, Kitchener H, Castellsagué X, Teixeira JC, Skinner SR, Jaisamrarn U, Limson GA, Garland SM, Szarewski A, Romanowski B, Aoki F, Schwarz TF, Poppe WA, De Carvalho NS, Harper DM, Bosch FX, Raillard A, Descamps D, Struyf F, Lehtinen M, Dubin G; for the HPV PATRICIA Study Group. Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. Gynecol Oncol. 127(3):440-450, 2012. ISSN: 0090-8258
41. Akogbe GO, Ajidahun A, Sirak B, Anic GM, Papenfuss MR, Fulp WJ, Hui-Yi Lin, Abrahamsen M, Villa LL, Lazcano-Ponce E, Quiterio M, Smith D, Schabath MB, Salmeron J, Giuliano AR. Race and prevalence of human papillomavirus infection among men residing in Brazil, Mexico, and the United States. Int J Cancer. 131(3):E282-91, 2013. ISSN: 0020-7136
42. Levinson KL, Abuelo C, Chyung E, Salmeron J, Belinson SE, Sologuren CV, Ortiz CS, Vallejos MJ, Belinson JL. The Peru Cervical Cancer Prevention Study (PERCAPS): Community-Based Participatory Research in Manchay, Peru. Int J Gynecol Cancer. 23(1):141-7, 2013. ISSN: 1048-891X
43. Albero G, Villa LL, Lazcano-Ponce E, Fulp W, Papenfuss MR, Nyitray AG, Lu B, Castellsagué X, Abrahamsen M, Smith D, Bosch FX, Salmerón J, Quiterio M, Giuliano AR. Male circumcision and prevalence of genital human papillomavirus infection in Men: a multinational study. BMC Infect Dis. 13:18, 2013. ISSN: 1471-2334
44. Levinson KL, Abuelo C, Salmeron J, Chyung E, Zou J, Belinson SE, Wang G, Ortiz CS, Vallejos CS, Belinson JL. The Peru Cervical Cancer Prevention Study (PERCAPS): The technology to make screening accessible. Gynecol Oncol. 129(2):318-23, 2013. ISSN: 0090-8258
45. Pierce Campbell CM, Lin HY, Fulp W, Papenfuss MR, Salmerón J, Quiterio M, Lazcano-Ponce E, Villa LL, Giuliano AR. Consistent Condom Use Reduces the Genital Human Papillomavirus Burden Among High-Risk Men: The HPV Infection in Men Study. J Infect Dis. 208(3):373-84, 2013. ISSN: 0022-1899.
46. Anic GM, Messina JL, Stoler MH, Rollison DE, Stockwell H, Villa LL, Lazcano-Ponce E, Gage C, Silva RJ, Baggio ML, Salmerón J, Giuliano AR. Concordance of human papillomavirus types detected on the surface and in the tissue of genital lesions in men. J Med Virol. 85(9):1561-6, 2013. ISSN: 0146-6615
47. Schabath MB, Villa LL, Lin HY, Fulp WJ, Akogbe GO, Abrahamsen ME, Papenfuss MR, Lazcano-Ponce E, Salmerón J, Quiterio M, Giuliano AR. Racial Differences in the Incidence and Clearance of Human Papilloma Virus (HPV): The HPV in Men (HIM) Study. Cancer Epidemiol Biomarkers Prev. 22(10):1762-1770, 2013. ISSN: 1055-9965
48. Torres-Mejía G, Ortega-Olvera C, Ángeles-Llerenas A, Villalobos-Hernández AL, Salmerón J, Lazcano-Ponce E, Hernández-Ávila M. Patrones de utilización de programas de prevención y diagnóstico temprano de cáncer en la mujer. Salud Pública de México. 55(2):S241-S248, 2013. ISSN: 0036-3634
49. Jaisamrarn U, Castellsagué X, Garland SM, Naud P, Palmroth J, Del Rosario-Raymundo MR, Wheeler CM, Salmerón J, Chow SN, Apter D, Teixeira JC, Skinner SR, Hedrick J, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WAJ, Bosch FX, de Carvalho NS, Germar MJ, Peters K, Paavonen J, Bozonnat MC, Descamps D, Struyf F, Dubin DO, Rosillon D, Baril L, for the HPV PATRICIA Study Group. Natural History of Progression of HPV Infection to Cervical Lesion or Clearance: Analysis of the control arm of the large randomised PATRICIA Study. PLoS One. 8(11):e79260, 2013. ISSN: 1932-6203
50. Schabath MB, Villa LL, Lin HY, Fulp WJ, Lazcano-Ponce E, Salmerón J, Abrahamsen ME, Papenfuss MR, Quiterio M, Giuliano AR. A prospective analysis of smoking and human papillomavirus infection among men in the HPV in Men Study. Int J Cancer. 134(10):2448-57, 2014. ISSN: 0020-7136
51. Lazcano-Ponce E, Lorincz A, Torres L, Salmerón J, Cruz A, Rojas R, Hernández P, Hernández M. Specimen Self-Collection and HPV DNA Screening in a Pilot Study of 100,242 women. Int J Cancer. 135(1):109-16, 2014. ISSN: 0020-7136
52. Abuelo CE, Levinson KL, Salmeron J, Sologuren CV, Fernandez MJ, Belinson JL. The Peru Cervical Cancer Screening Study (PERCAPS): The Design and Implementation of a Mother/Daughter Screen, Treat, and Vaccinate Program in the Peruvian Jungle. J Community Health. 39(3):409-15, 2014. ISSN: 0094-5145
53. Castellsagué X, Paavonen J, Jaisamrarn U, Wheeler CM, Skinner SR, Lehtinen M, Naud P, Chow SN, Del Rosario-Raymundo MR, Teixeira JC, Palmroth J, de Carvalho NS, Germar MJ, Peters K, Garland SM, Szarewski A, Poppe WA, Romanowski B, Schwarz TF, Tjalma WA, Bosch FX, Bozonnat MC, Struyf F, Dubin G, Rosillon D, Baril L; HPV PATRICIA Study Group.. Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial.BMC Infect Dis. 2014 Oct 30;14:551. doi: 10.1186/s12879-014-0551-y. PubMed PMID: 25927224; PubMed Central PMCID: PMC4251672.
54. Lazcano-Ponce E, Stanley M,  Muñoz N, Torres L, Cruz-Valdez A, Salmerón J, Rojas R, Herrero R, Hernández-Ávila M. Overcoming barriers to HPV vaccination: Non-inferiority of Antibody Response to Human Papillomavirus 16/18 Vaccine in Adolescents Vaccinated with a Two-dose vs. a Three-dose Schedule at 21 Months. Vaccine. 32(6):725-32, 2014. ISSN: 0264-410X
55. Albero G, Castellsagué X, Lin HY, Fulp W, Villa LL, Lazcano-Ponce E, Papenfuss M, Abrahamsen M, Salmerón J, Quiterio M, Nyitray AG, Lu B, Bosch FX, Giuliano AR. Male circumcision and the incidence and clearance of genital human papillomavirus (HPV) infection in men: the HPV Infection in men (HIM) cohort study. BMC Infect Dis. 14(1):75, 2014. ISSN: 1471-2334
56. Castellsagué X, Naud P, Chow SN, Wheeler CM, Germar MJ, Lehtinen M, Paavonen J, Jaisamrarn U, Garland SM, Salmerón J, Apter D, Kitchener H, Teixeira JC, Skinner SR, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, de Carvalho NS, Peters K, Tjalma WA, Safaeian M, Raillard A, Descamps D, Struyf F, Dubin G, Rosillon D, Baril L. Risk of newly detected infections and cervical abnormalities in women seropositive for naturally-acquired HPV-16/18 antibodies: analysis of the control arm of PATRICIA. J Infect Dis. 210(4):517-34, 2014. ISSN: 0022-1899.
57. G, Felix A, Clavero O, Lloveras B, Kasamatsu E, Goodman MT, Hernandez BY, Laco J, Tinoco L, Geraets DT, Lynch CF, Mandys V, Poljak M, Jach R, Verge J, Clavel C, Ndiaye C, Klaustermeier J, Cubilla A, Castellsagué X, Bravo IG, Pawlita M, Quint WG, Muñoz N, Bosch FX, de Sanjosé S; on behalf of the HPV VVAP study group. HPV DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer. 136(1):98-107, 2014. ISSN: 0020-7136
58. Alemany L, Saunier M, Tinoco L, Quirós B, Alvarado-Cabrero I, Alejo M, Joura EA, Maldonado P, Klaustermeier J, Salmerón J, Bergeron C, Petry KU, Guimerà N, Clavero O, Murillo R, Clavel C, Wain V, Geraets DT, Jach R, Cross P, Carrilho C, Molina C, Shin HR, Mandys V, Nowakowski AM, Vidal A, Lombardi L, Kitchener H, Sica AR, Magaña-León C, Pawlita M, Quint W, Bravo IG, Muñoz N, de Sanjosé S, Bosch FX; HPV VVAP study group. Large contribution of human papillomavirus in vaginal neoplastic lesions: A worldwide study in 597 samples. Eur J Cancer. 50(16):2846-54, 2014. ISSN: 0959-8049
59. Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano-Ponce E, Salmerón J, Del Rosario-Raymundo MR, Verheijen RH, Quek SC, da Silva DP, Kitchener H, Fong KL, Bouchard C, Money DM, Ilancheran A, Cruickshank ME, Levin MJ, Chatterjee A, Stapleton JT, Martens M, Quint W, David MP, Meric D, Hardt K, Descamps D, Geeraerts B, Struyf F, Dubin G; for the VIVIANE Study Group. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet. 384(9961):2213-27, 2014. ISSN: 0140-6736
60. Torres-Ibarra L, Conde-Glez CJ, Salmerón J, Palefsky J, Hernández-Neváres P, Sánchez-Alemán MA, Magis-Rodríguez C, Lazcano-Ponce E. Risk factors for anal HPV-16/18 infection in Mexican HIV-infected men who have sex with men. Prev Med. 69:157-164, 2014. ISSN: 0091-7435
61. Beal C, Salmerón J, Flores YN, Torres L, Granados‐Garcia V, Dugan E, Lazcano E. Cost analysis of different cervical cancer screening strategies in Mexico. Salud Pública de México. 56:492-501, 2014. ISSN: 0036-3634
62. Granados García V, Flores YN, Pérez R, Rudolph S, Lazcano E, Salmerón J. Costs of the Cervical Cancer Screening Program at the Mexican Institute of Social Security (IMSS). Salud Pública de México. 56:502-10, 2014. ISSN: 0036-3634
63. Struyf F, Colau B, Wheeler CM, Naud P, Garland S, Quint W, Chow S, Salmerón J, Lethinen M, Del Rosario-Raymundo MR, Paavonen J, Teixeira JC, Germar MJ, Peters K, Skinner R, Limson G, Castellsagué X, Poppe WA, Ramjattan B, Klein TD, Schwarz TF, Chatterjee A, Tjalma WA, Diaz-Mitoma F, Lewis DJ, Harper DM, Molijn A, van Doorn L, David M, Dubin G; for the HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against incident and persistent infection with non-vaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA: post hoc analysis from the PATRICIA randomized trial. Clin Vaccine Immunol. 22(2):235-44, 2015. ISSN: 1556-6811
64. Nyitray AG, Chang M, Villa LL, Carvalho da Silva RJ, Baggio ML, Abrahamsen M, Papenfuss M, Quiterio M, Salmerón J, Lazcano-Ponce E, Giuliano AR. The natural history of genital human papillomavirus among HIV-negative men having sex with men and men having sex with women. J Infect Dis. 212(2):202-12, 2015. ISSN: 0022-1899.
65. Apter D, Wheeler CM, Paavonen J, Castellsagué X, Garland SM, Skinner SR, Naud P, Salmerón J, Chow SN, Kitchener HC, Teixeira JC, Jaisamrarn U, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Mindel A, de Sutter P, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; for the HPV PATRICIA Study Group. Efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomised, double-blind PATRICIA trial. Clin Vaccine Immunol. 22(4):361-73, 2015. ISSN: 1556-6811
66. Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, Garland SM, Herrero R, David MP, Wheeler CM; Costa Rica Vaccine Trial and the PATRICIA study groups. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol. 16(7):775-86, 2015. ISSN: 1470-2045
67. Ingles DJ, Lin HY, Fulp WJ, Sudenga SL, Lu B, Schabath MB, Papenfuss MR, Abrahamsen ME, Salmeron J, Villa LL, Ponce EL, Giuliano AR. An analysis of HPV infection incidence and clearance by genotype and age in men: The HPV Infection in Men (HIM) Study. Papillomavirus Res. 1:126-135, 2015. ISSN: 2405-8521.
68. Giuliano AR, Viscidi R, Torres BN, Ingles DJ, Sudenga SL, Villa LL, Baggio ML, Abrahamsen M, Quiterio M, Salmeron J, Lazcano-Ponce E. Seroconversion Following Anal and Genital HPV Infection in Men: The HIM Study. Papillomavirus Res. 1:109-115, 2015. ISSN: 2405-8521
69. Hernández-Ávila M, Torres L, Stanley M, Salmerón J, Cruz-Valdez A, Muñoz N, Herrero R, Villaseñor-Ruíz IF, Lazcano-Ponce E. Evaluation of the immunogenicity of the quadrivalent HPV vaccine using two versus three doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes. Hum Vaccin Immunother. 12(1):30-8, 2016. ISSN: 2164-5515
70. Bosch FX, Robles C, Díaz M, Arbyn M, Baussano I, Clavel C, Ronco G, Dillner J, Lehtinen M, Petry KU, Poljak M, Kjaer SK, Meijer CJLM, Garland SM, Salmerón J, Castellsagué X, Bruni L, de Sanjosé S and Cuzick J. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Natur Rev Clin Oncol. 13(2):119-32, 2016. ISSN: 1759-4774.
71. León-Maldonado L, Wentzell E, Brown B, Allen-Leigh B, Torres-Ibarra L, Salmerón J, Billings DL, Thrasher JF, Lazcano-Ponce. Perceptions and Experiences of Human Papillomavirus (HPV) Infection and Testing among Low-Income Mexican Women. PLoS One. 11(5):e0153367, 2016. ISSN: 1932-6203
72. Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, Garland SM, Chatterjee A, Lazcano-Ponce E, Salmerón J, McNeil S, Stapleton JT, Bouchard C, Martens MG, Money DM, Quek SC, Romanowski B, Vallejos CS, Ter Harmsel B, Prilepskaya V, Fong KL, Kitchener H, Minkina G, Lim YK, Stoney T, Chakhtoura N, Cruickshank ME, Savicheva A, da Silva DP, Ferguson M, Molijn AC, Quint WG, Hardt K, Descamps D, Suryakiran PV, Karkada N, Geeraerts B, Dubin G, Struyf F, VIVIANE Study Group. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis. 16(10):1154-68, 2016. ISSN: 1473-3099.
73. Torres L, Lazcano E, Franco EL, Cuzick J, Hernández M, Lorincz A, Rivera B, Ramírez P, Pastrana I, Rudolph SE, Maldonado LL, Hernández R, Barrios E, Gravitt P, Moscicki AB, Schmeler KM, Flores YN, Méndez P, Salmerón J for the FRIDA Study Group. Triage strategies in cervical cancer detection in Mexico: methods of the FRIDA Study. Salud Publica Mex. 58(2):197-210, 2016. ISSN: 0036-3634.
74. Pinto LA, Kemp TJ, Torres BN, Isaacs K, Ingles D, Abrahamsen M, Pan Y, Lazcano-Ponce E, Salmeron J, Giuliano AR. The quadrivalent HPV vaccine induces HPV-specific antibodies at the oral cavity: results from the mid-adult male vaccine trial-the mam trial. J Infect Dis. 214(8):1276-83, 2016. ISSN: 0022-1899.
75. Liu Z, Nyitray AG, Hwang LY, Swartz MD, Abrahamsen M, Lazcano-Ponce E, Salmerón J, Quiterio M, Villa LL, Giuliano AR, Baggio ML, Silva RJ. Human Papillomavirus Prevalence among 88 male virgins residing in Brazil, Mexico, and the United States. J Infect Dis. 214(8):1188-91, 2016. ISSN: 0022-1899.
76. Garland SM, Paavonen J, Jaisamrarn U, Naud P, Salmerón J, Chow SN, Apter D, Castellsagué X, Teixeira JC, Skinner SR, Hedrick J, Limson G, Schwarz TF, Poppe WA, Bosch FX, de Carvalho NS, Germar MJ, Peters K, Del Rosario-Raymundo MR, Catteau G, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group. Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial. Int J Cancer. 139(12):2812-2826, 2016. ISSN: 0020-7136
77. Pamnani SJ, Sudenga SL, Viscidi R, Rollison DE, Torres BN, Ingles DJ, Abrahamsen M, Villa LL, Lazcano-Ponce E, Salmeron J, Quiterio M, Huang Y, Borenstein A, Giuliano AR. Impact of serum antibodies to HPV serotypes 6, 11, 16, 18 to risks of subsequent genital HPV infections in men: the HIM Study. Cancer Res. 76(20):6066-6075, 2016. ISSN: 0008-5472
78. Rudolph SE, Lorincz A, Wheeler CM, Gravitt P, Lazcano-Ponce E, Torres-Ibarra L, León-Maldonado L, Ramírez P, Rivera B, Hernández R, Franco EL, Cuzick J, Méndez-Hernández P, Salmerón J, FRIDA Study Group. Population-based prevalence of cervical infection with human papillomavirus genotypes 16 and 18 and other high risk types in Tlaxcala, Mexico. BMC Infect Dis. 16:461, 2016. ISSN: 1471-2334
79. Huitrón-Bravo G, Denova-Gutiérrez E, Talavera JO, Moran-Villota C, Tamayo J, Omaña-Covarrubias A, Salmerón J. Levels of serum estradiol and lifestyle factors related with bone mineral density in premenopausal Mexican women: a cross-sectional analysis. BMC Musculoskelet Disord. 17(1):437, 2016. ISSN: 1471-2474.
80. Sudenga SL, Nelson Torres B, Fulp WJ, Silva R, Villa LL, Lazcano-Ponce E, Ingles DJ, Stoler M, Messina JL, Abrahamsen M, Baggio ML, Salmeron J, Quiterio M, Giuliano AR. Country-Specific HPV-related Genital Disease Among Men Residing in Brazil, Mexico, and the United States: The HIM Study. Int J Cancer. 140(2):337-345, 2017. ISSN: 0020-7136.
81. Sudenga SL, Nyitray AG, Torres BN, Silva R, Villa L, Lazcano-Ponce E, Abrahamsen M, Baggio ML,Salmeron J, Quiterio M, Giuliano AR. Comparison of anal HPV natural history among men by country of residence: Brazil, Mexico, and the United States. J Infect. 75(1):35-47, 2017. ISSN: 0163-4453.
82. Rodríguez AC, Salmerón J. Cervical cancer prevention in upper middle-income countries. Prev Med.98:36-38, 2017. ISSN: 0091-7435.
83. Sudenga S, Torres BN, Carvalho da Silva RJ, Villa LL, Lazcano-Ponce E, Abrahamsen M, Baggio ML, Salmeron J, Quiterio M, Giuliano AR. Comparison of the natural history of genital HPV infection among men by country: Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev.26(7):1043-1052, 2017. ISSN: 1055-9965
84. Safaeian M, Castellsagué X, Hildesheim A, Wacholder S, Schiffman MH, Bozonnat MC, Baril L, Rosillon D; Costa Rica HPV Vaccine Trial and the PATRICIA study groups. (Salmerón J, como parte del Patricia Study Group) Risk of HPV-16/18 Infections and Associated Cervical Abnormalities in Women Seropositive for Naturally Acquired Antibodies: Pooled Analysis Based on Control Arms of Two Large Clinical Trials. J Infect Dis.2018 Jun 5;218(1):84-94. ISSN: 0022-1899
85. Gilca V, Salmerón-Castro J, Sauvageau C, Ogilvie G, Landry M, Naus M, Lazcano E. Early use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact. Vaccine. 7 June 2018. [Epub ahead of print]. ISSN: 0264-410X
86. Lazcano-Ponce E, Torres-Ibarra L, Cruz-Valdez A, Salmerón J, Barrientos-Gutiérrez T, Prado-Galbarro J, Stanley M, Muñoz N, Herrero R, Hernández-Ávila M. Persistence of immunity when using different HPV vaccination schedules and booster dose effects at 5 years post-primary vaccination.J Infect Dis. 2018 Aug 1. [Epub ahead of print]. ISSN: 0022-1899
87. Flores Y, Salmerón J, Glenn BA, Lang CM, Chang CL, Guerra M, Bastani R. Clinician offering is a key factor associated with HPV vaccine uptake among Mexican mothers in the U.S. and Mexico: a cross-sectional study. Int J Public Health.2018 Dec 1. [Epub ahead of print]. ISSN: 1661-8564
88. Lazcano-Ponce E, Sudenga SL, Torres BN, Stoler M, León-Maldonado L, Allen-Leigh B, Posso H, Quiterio M, Nernández-Nevares MP. Salmerón J, Giuliano AR. Incidence of external genital lesions related to human papillomavirus among Mexican men. A cohort Salud Publica Mex. 2018 Nov-Dic;60(6):633-644. ISSN 1606-7916.
89. Posso H, León-Maldonado L, Allen-Leigh B, Salmerón J, Quiterio M, Giuliano AR, Sudenga SL, Nyitray AG, Torres BN, Abrahmsen M, Lazcano-Ponce E. Prevalence and incidence of anal human papillomavirus infection in Mexican men: Need for universal prevention policies. Salud Publica Mex. 2018 Nov-Dic;60(6):645-652. ISSN 1606-7916.
90. Portillo-Romero AJ, León-Maldonado L, Allen-Leigh B, Brown B, Magis C, García-Fuentes NB, Salmerón J, Hurtado E, Torres-Ibarra L, Rivera-Paredez B, Hernández-López R, Yunes-Díaz E, Lazcano-Ponce E. HPV vaccine Acceptance is high among adults in Mexico, particularly in people living with HIV. Salud Publica Mex. 2018 Nov-Dic;60(6):658-665. ISSN 1606-7916.
91. Lazcano-Ponce E, Carnalla-Cortés M, Barrientos-Gutiérrez T, Torres-Ibarra L, Cruz-Valdez A, Salmerón J, Hernández-Ávila M. The effect of a booster dose of HPV tetravalent vaccine after 51 months: implications for extended vaccination schedules. Salud Publica Mex. 2018 Nov-Dic;60(6):666-673. ISSN 1606-7916.
92. Lazcano-Ponce E, Salmerón J, González A, Allen-Leigh B, León-Maldonado L, Magis C, Aranda-Flores C, Conde González C, Portillo-Romero AJ, Yunes-Díaz E, Rivera-Rivera L, Vargas G, Nyitray AG, Giuliano AR. Prevention and control of neoplasms associated with HPV in high-risk groups in Mexico City: The Condesa Study. Salud Publica Mex. 2018 Nov-Dic;60(6):703-712. ISSN 1606-7916.
93. Hurtado-Salgado E, Ortiz-Panozo E, Salmerón J, Saavedra-Lara N, Kuri-Morales P, Pesqueira-Villegas E, Luna-Gordillo R, Franco EL, Lazcano-Ponce E. Use of HPV testing in cervical cancer screening services in Mexico, 2008-2018: a nationwide database study. Salud Publica Mex. 2018 Nov-Dic;60(6):722-733. ISSN 1606-7916.

 

1. Lazcano CE, Moss S, Alonso P, Salmerón J, Hernández M. Programa de detección oportuna de cáncer de cuello uterino en países en vías de desarrollo: el caso de México, en Alonso P, Lazcano EC, Hernández M (Eds). Cáncer Cervicouterino: Diagnóstico, Prevención y Control. Editorial Médica Panamericana-UNAM-INSP, México DF, 2000 p.155-174. ISBN 968-7988-06-1. 84-7903-561-7. (Incluido en la Primera y la Segunda edición).
2. Flores Y, Bishai D, Lazcano EC, Shah K, Lorincz A, Hernández M, Salmerón J. Evaluación del uso de la prueba de VPH como alternativa de detección de cáncer cervical en México. En Durán L y Muñoz O. (Eds) Retos de la Seguridad Social en Salud en el Siglo XXI. Instituto Mexicano del Seguro Social, México, DF, 2002.
3. Alonso de Ruiz P, Duperval PA, Lazcano-Ponce E, Ruiz-Moreno JA, Salmerón J, Schiavon-Ermani R, Valdespino-Gómez JL, Vieyra-Ávila A. Infección de transmisión sexual por virus de papiloma humano en mujeres. en Práctica Médica Efectiva. México DF, 2005; 7(1). ISSN 1665-0506.

 

Capítulos en libros

 

1. Flores I, Bishai D, Lazcano E, Shah K, Lörincz AT, Hernández M, Salmerón J. Determinación del VPH de alto riesgo como estrategia de detección oportuna del cáncer cervicouterino: el estudio de Morelos, en México. En Alonso P, Lazcano EC, Hernández M (Eds). Cáncer Cervicouterino, Diagnóstico, Prevención y Control, 2a edición. Editorial Médica Panamericana,  México DF, 2005. p. 277-289. ISBN 988-6502-98-X.
2. Lazcano-Ponce E, León-Maldonado L, Allen-Leigh B, Salmerón J, Hernández-Ávila M. Control and Prevention in Cervical Cancer. En De la Garza-Salazar JG, Morales-Vásquez F, Meneses-Garcia A. (Eds) Cervical Cancer. Springer International Publishing. 2017. DOI 10.1007/978-3-319-45231-9_6. Print ISBN: 978-3-319-45230-2. Online ISBN: 978-3-319-45231-9.
3. Granados V, Flores YN, Perez R, Rudolph SE, Lazcano E, Leon L, Salmeron J. Costo del programa de tamizaje de cáncer cervical en el Instituto Mexicano del Seguro Social. En Alonso P, Lazcano E. Cáncer del cuello uterino. Del diagnóstico a la salud pública. Salud Pública de México. Primera edición, 2018. ISBN: 978-607-511-172-8.
4. Beal C, Salmeron J, Flores YN, Torres L, Granados V, Dugan E, Maldonado L, Lazcano E. Costoefectividad de distintas estrategias de tamizaje para cáncer cervical en México. En Alonso P, Lazcano E. Cáncer del cuello uterino. Del diagnóstico a la salud pública. Salud Pública de México. Primera edición, 2018. ISBN: 978-607-511-172-8.
5. Torres Ibarra L, Wheeler C, Gravitt P, Stoler M, Carmona E, Figueroa H, Ault K, Schmeler K, Castle P, Granados V, Bishai D, Ramirez P, Hernandez P, Maldonado L, Alvarez D, Barrios E, Hernandez R, Mendiola I, Gonzalez V, Hernandez M, Lazcano E, Franco E, Cuzick J, Lorincz A, Wright T, Moscicki A, Flores Y, Meneses J, Mendez P, Rivera B, Rudolph S, Salmeron J. Estrategias de triaje en la detección de cáncer cervical en México: métodos del Estudio FRIDA. En Alonso P, Lazcano E. Cáncer del cuello uterino. Del diagnóstico a la salud pública. Salud Pública de México. Primera edición, 2018. ISBN: 978-607-511-172-8.
6. Salmerón J, Torres L, Bosch X, Cuzick J, Lörincz A, Wheeler C, Castle P, Robles C, Maldonado L, Lazcano E. Impacto de la vacunación contra VPH en el programa de tamizaje de cáncer cervical: métodos del Estudio FASTER-Tlalpan en México. En Alonso P, Lazcano E. Cáncer del cuello uterino. Del diagnóstico a la salud pública. Salud Pública de México. Primera edición, 2018. ISBN: 978-607-511-172-8.
7. Lazcano E, Stanley M, Villaseñor I, Salmerón J, Cruz A, Maldonado L, Hernández M. Innovación en la prevención del cáncer cervical. Evaluación de la efectividad de la vacuna contra VPH en esquemas alternativos aplicados en niñas entre 10 y 12 años, 2010-2016. En Alonso P, Lazcano E. Cáncer del cuello uterino. Del diagnóstico a la salud pública. Salud Pública de México. Primera edición, 2018. ISBN: 978-607-511-172-8.
8. Maldonado L, Allen B, Lazcano E. Consejería en la detección de VPH como prueba de tamizaje de cáncer cervical: un estudio cualitativo sobre necesidades de mujeres de Michoacán, México. En Alonso P, Lazcano E. Cáncer del cuello uterino. Del diagnóstico a la salud pública. Salud Pública de México. Primera edición, 2018. ISBN: 978-607-511-172-8.
9. Lazcano E, Salmerón J, González A, Allen B, Maldonado L, Magis C, Aranda C, Conde C, Jalil A, Yunes E, Rivera L, Vargas G, Nyitray A. Prevención y control de neoplasias asociadas a VPH en grupos de alto riesgo de la Ciudad de México: una intervención con dimensión social. En Alonso P, Lazcano E. Cáncer del cuello uterino. Del diagnóstico a la salud pública. Salud Pública de México. Primera edición, 2018. ISBN: 978-607-511-172-8.
10. Hurtado E, Torres L, Rivera B, León-Maldonado L, Salmerón J, Hernández R, Portillo AJ, Meneses J, Méndez P, Lazcano-Ponce E. Prevención y manejo de la infección por virus de papiloma humano en población que vive con el VIH. Instituto Nacional de Salud Pública. Primera edición, 2018. ISBN: 978-607-511-174-2.